Klinrisk

Klinrisk improves CKD progression risk discrimination relative to KDIGO heat-map categories in humans.

“It outperformed KDIGO heat-map categories in subgroups of patients with and without type 2 diabetes, and in those with IgA nephropathy.”

HumansSubgroups with and without type 2 diabetes and with IgA nephropathy

Validation of the Klinrisk CKD Progression Model in the Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) Population

Kidney360·13 Oct 2026

Klinrisk predicts CKD progression in humans (AUC 0.79, 95% CI 0.77–0.81).

“Klinrisk achieved an AUC of 0.79 (95% CI 0.77-0.81) and a Brier score of 0.10 (95% CI 0.09-0.11).”

HumansDAPA-CKD participants; eight of 22 model inputs supplied from the development model rather than measuredUp to 3 yearsn = 4,304

Validation of the Klinrisk CKD Progression Model in the Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) Population

Kidney360·13 Oct 2026